8-K current report · filed Nov 9, 2026

Viridian Therapeutics, Inc.\DE (VRDN) 8-K Current Report: November 9, 2026

Item 7.01Item 8.01Item EX-99.1VRDN overview

Short answer

Viridian Therapeutics, Inc.\DE (VRDN) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Phase 1 data announced for VRDN-008, a half-life extended bispecific FcRn inhibitor.

Viridian Therapeutics, Inc.\DE 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Phase 1 data announced for VRDN-008, a half-life extended bispecific FcRn inhibitor
  • Results come from healthy volunteers, providing early safety, pharmacokinetic and dosing evidence
  • Exhibit 99.1 contains the detailed trial findings, critical for assessing clinical differentiation and development potential

Item 8.01 · Other Events

  • VRDN-008 achieved 74% peak IgG reduction in six healthy volunteers, supporting potential FcRn inhibitor efficacy
  • Half-life 15 to 18 days, enabling targeted Q8W subcutaneous dosing
  • Safety profile generally well tolerated, with albumin and low-density lipoprotein sparing
  • Planned pivotal MG trial in mid-2027, testing Q4W and Q8W dosing versus placebo
  • Development focus shifts to VRDN-008, with VRDN-006 potentially deferred

Item EX-99.1 · Exhibit EX-99.1

  • Phase 1 supports VRDN-008’s potential differentiation: 74% peak IgG reduction sustained through 8 weeks
  • Half-life 15–18 days, up to 6x longer than first-generation Fc fragments
  • Safety profile generally well tolerated, with albumin and LDL spared and no serious adverse events
  • Registrational MG trial planned for mid-2027, testing Q4W and Q8W dosing versus placebo
  • At-home enFuse delivery could strengthen convenience and commercial positioning across autoimmune diseases

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Viridian Therapeutics, Inc.\DE 8-K filings

Get the next VRDN 8-K as it lands

Follow VRDN for push alerts, or ask the research agent what this filing means.